CompanyGraph
Turns purchased raw ingredients into branded dietary supplements, mostly made in its own factories, and sells them through a broad mix of distributors, retailers and online platforms across China and abroad.
- Pays more per share than it earned over the last twelve months
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $2.44B, above the global median of $1.18B
- PositionGross margin is 71.6%, higher than 95% of its Packaged Foods peers (median 29.7%)
- Interpretations2 currently firing — 1 · 1
What this company is and how it runs — written from structure, not news.
The company sits in the middle of its supply chain: it draws on a range of upstream material and manufacturing relationships, converts those inputs into finished, packaged supplements inside its own plants, and then pushes the branded output back out through a similarly wide set of downstream relationships, including distributors, pharmacies, supermarkets, e-commerce platforms and its own direct online stores. By its own account it also carries out formulation and quality work to support that manufacturing step.
Revenue comes from one-time product sales rather than subscriptions, fees or recurring service charges. By its own account, the company sells through a mix of wholesale buyout, consignment and direct-online arrangements, spread across several supplement formats, with most transactions settled at or near delivery rather than through extended credit. The large majority of sales are domestic, with a smaller share earned outside its home market.
The company scales mainly by adding manufacturing capacity through large, multi-year construction projects, funded from its own resources rather than borrowed money: its cash position comfortably exceeds its debt and its balance sheet leans heavily toward equity. By its own account, however, recently planned capacity has been arriving ahead of demand: its expansion planning already assumes capacity needs below original targets, and the company itself warns that softer market demand could leave new capacity underused. At the same time, it returns a large share of earnings to shareholders as dividends, at a level that has exceeded per-share earnings, so growth spending and shareholder payouts draw on the same internally generated cash.
By its own account, the company depends on raw materials sourced globally, which it says exposes it to input-price swings and, if sales grow quickly, potential shortages; it manages this through multiple suppliers, substitute materials and locked-in pricing arrangements rather than a single source. Some newer product forms are made by outside contract manufacturers it does not name. It also depends on holding a large number of product-level health and safety approvals from national regulators in order to keep existing products on sale.
The company's own disclosures describe a broad base of downstream buyers: distributors, pharmacies, supermarkets and named e-commerce platforms including Alibaba, JD.com, Tmall, Vipshop, Douyin and Kuaishou, alongside direct sales through its own online stores. One customer, not otherwise identified, is large enough that the company must disclose it separately, but no other single buyer is flagged at that scale, so the remaining demand appears spread across many retail and platform relationships rather than concentrated in a few accounts.
This kind of production-and-brand system is not rare: CompanyGraph maps a substantial number of other companies operating under the same brand-driven production economics. By its own account, the company points to proprietary product formulations, in-house manufacturing and quality control, a wide portfolio of brands, and broad coverage across both offline retail and online platforms as what sets it apart, and it cites an outside research firm's data placing it first by retail sales in its home market's vitamin and supplement category. CompanyGraph has not independently tested whether rival companies could reproduce these specific strengths, so this describes the company's own stated position rather than a measured barrier to imitation.
By its own account, the limit it describes sits more on the demand side than the supply side: it says capacity demand is running below its original plan and that softer market demand could leave newly built capacity underused, even as it continues large, multi-year plant expansions. It also names industry competition and a changing retail-channel structure as forces that have made growth fall short of its own expectations. Separately, it flags that a strong rebound in sales could itself strain raw-material sourcing. This is the company's own framing of what limits it, and it sits apart from a pure brand-strength constraint, leaning instead on matching new production capacity to actual demand and navigating a shifting competitive and channel landscape.
The company's own risk disclosures put product quality and food safety first among the things that could hurt it, ahead of policy shifts, raw-material cost and supply effects, and competitive pressure. A single, unnamed customer accounts for a share of revenue large enough to require separate disclosure, marking a point of revenue concentration. It also carries an unresolved lawsuit tied to an equity-transfer dispute, sent back for a new hearing, whose financial effect it says it cannot yet quantify. Separately, CompanyGraph's own computation shows the company paying shareholders more per share than it earned over the trailing year; a strong cash position and a multi-year run of positive free cash flow can absorb that gap for a time, but continuing it would draw down that buffer.
By its own account, the company operates under approval and inspection regimes run by national market-regulation, health and traditional-medicine authorities, which must clear individual health-food products before sale, plus separate certification requirements in some overseas markets it serves. Among the risks it lists, it puts product quality and food safety first, ahead of policy shifts, raw-material cost and supply effects, and competitive intensity in its industry. It also discloses an unresolved lawsuit tied to an equity-transfer dispute that a higher court sent back for a new hearing, with the financial effect not yet determined, and it holds meaningful foreign-currency balances across a wide range of currencies tied to its overseas operations.
Read from the company's own filings and public materials (gathered August 2026) together with figures CompanyGraph recomputed from its statements. Written September 2026. A question with no evidence behind it is left out rather than answered.
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
- Pays more per share than it earned over the last twelve months
Screen for this company's dividend patterns
Find other companies where the same dividend readings fire.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company return capital?
High Dividend Payout With FCF And Equity Ratio
It pays out most of its earnings, on three years of positive free cash flow.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
The reported statements, read against the company's own industry.
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Structural Tensions
Financial Health
Supply Chain
Scale
Companies that share the same coordination system — how they create, deliver, or capture value.
Companies that share active interpretations — structural patterns currently present in both stocks.
Supply Chain
Beef Supply Chain
Follow cattle from feed and biological growth through transport, slaughter, carcass balance, processing, cold storage, cooking, and recovery. One animal becomes many outputs while grinding merges many identities, so time, traceability, welfare, and money determine usable food.
Cocoa Supply Chain
Follow cacao from tree and pod through harvest, fermentation, drying, aggregation, factory separation, chocolate manufacture, use, and residuals. The bean is not the constant object: each stage creates a new condition and closes earlier options.
Coffee Supply Chain
Coffee can reach the cup even when much of its history has disappeared. Follow the chain to see what gets damaged, what money makes possible, what records can prove, and where responsibility breaks.
Processed Food Supply Chain
Follow food from biological ingredients through formulation, preservation, packaging, distribution, and consumption. The chain carries nutrition and culinary function, but each processing step creates conditions, losses, waste, and records that only partly describe what a person finally eats.
Seafood Supply Chain
Follow wild or farmed seafood through harvest, chilling, processing, sale, consumption, and residuals. Biological renewal before harvest and irreversible quality loss after it make quotas, ice, payment, identity, and feedback part of the food supply.
Sugar Supply Chain
Follow sucrose from a living cane stalk or beet root into a uniform crystal, then through food, fermentation, and residues—and see what concentration makes possible and what it disconnects.